The financing will support continued advancement of the clinical trial for SynKIR-110™, a first-in-class KIR-CAR T cell immunotherapy candidate for solid tumors, and pre-clinical development of SynKIR-310, a KIR-CAR T cell immunotherapy therapeutic for blood cancer.

The funding round was led by BRV Capital Management (BRV Capital), a renowned institutional investment firm known for investing in blue-chip biopharmaceutical companies such as Arvelle Therapeutics BV and ST Pharmaceutical. Verismo will be BRV Capital's newest early-stage investment in the life science space. Lead investor BRV Capital was joined by Ignite Innovation. With this $7M investment Verismo will have secured a total of $33M in financing since launching in 2020.

Verismo Therapeutics is a pioneer in dual-chain KIR-CAR technology, on track to bring its first asset into first-in-human clinical trials in 2023. Verismo is the only company developing the KIR-CAR platform, a modified NK-like receptor designed to improve persistence and efficacy against aggressive solid tumors. The KIR-CAR platform technology was developed specifically for advanced solid tumors, an area of high unmet medical need.